Take­da con­tin­ues post-Shire sell­off, inch­ing clos­er to $10B goal

The Take­da sell­off con­tin­ues.

In the lat­est of the Japan­ese phar­ma’s post-merg­er trim­mings, Take­da has sold off a port­fo­lio of “non-core” over-the-counter and pre­scrip­tion prod­ucts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER